Last Updated: November 16, 2026

Investigational Drug Information for UGN-102

« Back to Dashboard


What is the drug development status for UGN-102?

UGN-102 is an investigational drug.

There have been 5 clinical trials for UGN-102. The most recent clinical trial was a Phase 2 trial, which was initiated on August 29th 2024.

The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, and Carcinoma. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for UGN-102
TitleSponsorPhase
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerUroGen Pharma Ltd.PHASE3
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerUroGen Pharma Ltd.Phase 3
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd.Phase 3

See all UGN-102 clinical trials

Clinical Trial Summary for UGN-102

Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102

See all UGN-102 clinical trials

US Patents for UGN-102

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
UGN-102 ⤷  Start Trial Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same Immunogen Inc ⤷  Start Trial
UGN-102 ⤷  Start Trial Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same Samsung Life Public Welfare Foundation ⤷  Start Trial
UGN-102 ⤷  Start Trial Bio-orthogonal drug activation Tagworks Pharmaceuticals BV ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.